According to the FDA: The agency gave Novo Nordisk 15 working days to respond and correct the violations
Despite the common use of pharmacotherapy in obesity management, sarcopenia and SO remain significant concerns [12]
Researchers tracking full lipid panels should anticipate the most dramatic changes in the triglyceride and HDL fractions when studying higher retatrutide doses
The success of these therapies has paved the way for the development of next-generation treatments, including multi-agonist molecules like Tirzepatide (Mounjaro/Zepbound) or Retatrutide (LY3437943) that simultaneously target several metabolic receptors to achieve improved metabolic outcomes in obese or diabetic patients [3,6]
GLP-1 medications offer life-changing support, but their full benefits are realized when the body feels nourished, muscle is protected, and treatment is guided by a team that understands the nuances of medical weight loss
Many people start to see noticeable results within the first few weeks of beginning treatment
